The development of PARP inhibitors (PARPi) has revolutionized cancer treatment, particularly for BRCA1/2 deficient tumors. However, the emergence of PARPi resistance poses a significant challenge. Our study aimed to explore the mechanisms of this resistance, focusing on the role of DNA end resection.
We induced resistance in the MDA-MB-468 cell line using Talazoparib and Olaparib, creating in vivo models to evaluate drug sensitivity. RNA-seq analysis identified significant gene expression changes in resistant cells, hinting at altered signaling pathways.
Our results showed increased resistance indices and poor drug response in resistant cell lines, confirming resistance development. Establishing over 40 drug-resistant cell lines, our platform is poised to facilitate the advancement of PARP targeted therapies, offering insights into overcoming PARPi resistance in cancer treatment.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
